Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 620 participants.
Also called NCT05976893
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 620 participants
- Sponsor
- Xiang Xie
- Registry
-
NCT05976893
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05976893. Randomized; single masking; primary purpose treatment. Start 2023-08-01 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
- Condition
- ASCVD
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Condition
- Cancer
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Statin
- Lead sponsor
- Xiang Xie
- Collaborator
- Xinjiang Medical University
Record details
- Record id
cardio:ct-nct05976893- Content hash
7d10a0b5fe977fa51c1fb66b1cabe333007d3a4f1710c89bd1e7e8cd9829f9e6